



Published in final edited form as:

ACS Appl Mater Interfaces. 2013 June 12; 5(11): 4632–4639. doi:10.1021/am400713j.

Casein-coated Iron Oxide Nanoparticles for High MRI Contrast Enhancement and Efficient Cell Targeting

Jing Huang[†], Liya Wang[†], Run Lin^{†,‡}, Andrew Y. Wang[§], Lily Yang^{±,||}, Min Kuang[§], Weiping Qian[±], and Hui Mao^{†,||,*}

[†]Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA

[‡]Department of Interventional Radiology, Sun Ye-Tzen University School of Medicine, Guangzhou, Guangdong 510080, China

[§]Ocean NanoTech, LLC, Springdale, Arkansas 72764, USA

[±]Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA

^{||}Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA

Abstract

Surface properties, as well as inherent physicochemical properties, of the engineered nanomaterials play important roles in their interactions with the biological systems, which eventually affect their efficiency in diagnostic and therapeutic applications. Here we report a new class MRI contrast agent based on milk casein protein coated iron oxide nanoparticles (CNIOs) with a core size of 15 nm and hydrodynamic diameter ~30 nm. These CNIOs exhibited excellent water-solubility, colloidal stability, and biocompatibility. Importantly, CNIOs exhibited prominent T₂ enhancing capability with a transverse relaxivity r₂ of 273 mM⁻¹s⁻¹ at 3 Tesla. The transverse relaxivity is ~2.5-fold higher than that of iron oxide nanoparticles with the same core but an amphiphilic polymer coating. CNIOs showed pH-responsive properties, formed loose and soluble aggregates near the pI (pH~4.0). The aggregates could be dissociated reversibly when the solution pH was adjusted away from the pI. The transverse relaxation property and MRI contrast enhancing effect of CNIOs remained unchanged in the pH range of 2.0 to 8.0. Further functionalization of CNIOs can be achieved via surface modification of the protein coating. Bio-affinitive ligands, such as a single chain fragment from the antibody of epidermal growth factor receptor (ScFvEGFR), could be readily conjugated onto the protein coating, enabling specific targeting to MDA-MB-231 breast cancer cells over-expressing EGFR. T₂-weighted MRI of mice intravenously administered with CNIOs demonstrated strong contrast enhancement in the liver and spleen. These favorable properties suggest CNIOs as a class of biomarker targeted magnetic nanoparticles for MRI contrast enhancement and related biomedical applications.

Keywords

iron; oxide; nanoparticles; magnetic resonance; imaging; casein; contrast agent; targeting

*Address correspondence: to hmao@emory.edu.

Supporting Information Available: 1) Reversible size change, TEM images and UV-vis absorption at different pH conditions. 2) Magnetic susceptibility measurement and comparisons of CNIO and SPH15. Supporting Information and related materials are available free of charge via the Internet at <http://pubs.acs.org>.

INTRODUCTION

Magnetic iron oxide (IO, i.e., Fe_3O_4 , $\gamma\text{-Fe}_2\text{O}_3$) nanoparticles have attracted extensive attention due to their biomedical applications in cell labeling, magnetic resonance imaging (MRI), and imaging-guided drug delivery.^{1–5} IO nanoparticles synthesized via pyrolysis of organometallic iron precursors possess high uniformity and excellent magnetic properties. However, due to the inevitable hydrophobic residues (i.e., oleic acid) on the surface, they have poor water solubility for biomedical applications. Increasing efforts are devoted to fabricate biocompatible IO nanoparticles with functional coatings, including synthetic polymers and natural products (e.g., proteins). Conventionally, the phase transfer process of high quality hydrophobic IO nanoparticles to aqueous phase is based on exchanging surface surfactants with amphiphilic molecules, such as polyethylene glycol (PEG), PEG phospholipid, dextran, poly(acrylic acid) (PAA), polyethylenimine (PEI), or glutathione (GSH), etc.^{6–11} However, this exchange method usually requires reactions (heating or sonicating) between IO nanoparticles and coating materials in a dipolar solvent (e.g., dimethyl sulfoxide, DMSO), and is not applicable for protein coating. Although IO-protein complex could be fabricated through directly mixing the aqueous protein solution and hydrophobic IO nanoparticles, large clusters may form due to the incompatibility of those two components.¹² In addition, biomimetic magnetic nanoparticles can be formed by co-precipitating ferric and ferrous salt inside protein cages, or post-synthesis encapsulating.^{13–18} However, the biomineralization or co-precipitation under mild conditions typically yields magnetic nanoparticles with limited magnetic properties. Therefore, a simple and reliable strategy for fabricating protein coated IO nanoparticles needs to be developed.

Casein (CN) is a main ingredient (~80%) of bovine milk that contains several related phosphoproteins. Specifically, bovine casein is consisted of four types of phosphoproteins (i.e., αS_1 -, αS_2 -, β -, and κ -CN) with molecular weight of 19–25 kDa, and an isoelectric point (pI) of 4.2–5.8.^{19,20} Casein has high affinity to bind ions or small molecules. Naturally, casein self-assembles into micelles with diameters ranging from 50–500 nm, acting as natural nanovehicles for delivery of calcium, phosphate and other biomolecules.^{21–26} Generally, the casein micelle is believed to be formed based on the open structure and distinct hydrophobic/hydrophilic domains of these proline-rich phosphoproteins, which allow casein to change its conformation easily in solution. Casein micelle is stabilized by an out layer of hair-like κ -casein molecules, which protrude their hydrophilic C-terminal domains into the aqueous environment. In addition to its excellent biocompatibility and biodegradability, casein has pH-responsive structural, conformational and functional changes, and is heat-stable up to 60–70 °C.^{27–29} These unique structural and physicochemical properties have led to the earlier studies of casein-based drug delivery systems.^{30–36}

In this work, we present the development of casein-coated iron oxide nanoparticles (CNIOs) for biomarker targeted MRI. Since conventional exchange methods require harsh reaction conditions which can easily denature proteins and deform the nanoparticle surface structure, we use a recently developed exchange-encapsulation method to transfer high quality hydrophobic IO nanoparticles to the aqueous phase.³⁷ This process, as illustrated in Scheme 1, is mediated by a widely available natural nutrient molecule, glucose, which can be oxidized and polymerized into oligosaccharides under high temperature conditions.^{38,39} For the current study these oligosaccharide molecules partially replace oleic acid and protect hydrophobic IO nanoparticles from oxidation during the exchange procedure. The ionic oligosaccharide renders hydrophilic moieties of protein molecules onto the surface of IO nanoparticle cores. This new approach allows the robust preparation of nanomaterials with a desired protein coating, resulted in water soluble and stable nanocolloids for biomedical

applications. Such milk protein coated iron oxide nanoparticles exhibit a significantly higher transverse relaxivity than that of the same nanoparticulate core coated with synthetic polymer, providing a highly efficient MRI contrast agent. More importantly, bio-affinitive ligands, such as single chain fragment from the antibody of epidermal growth factor receptor (ScFvEGFR), can be readily conjugated onto the protein coating, enabling specific targeting to tumor cells for targeted molecular imaging and drug delivery applications.

MATERIALS AND METHODS

Materials

All materials were used as received. Bovine casein, glucose, glutaraldehyde, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (Sulfo-NHS) were obtained from Thermo Scientific (Rockford, IL). All cell culture materials (media and supplements) were purchased from Invitrogen (Burlington, ON). 100 kDa MWCO Ultra-4 centrifuge tubes were purchased from Millipore (Billerica, MA).

Synthesis of casein-coated iron oxide nanoparticles (CNIOs)

Hydrophobic iron oxide (IO) nanoparticles were prepared by heating iron oxide powder and oleic acid in octadecene at 315 °C.⁴⁰ To transfer IO nanoparticles into aqueous phase, a chloroform solution of IO nanoparticles was added to a preheated glucose/DMF solution with a molar ratio of IO nanoparticle:glucose at 1:10⁵. The mixture was refluxed for 1 h, and then cooled to room temperature. IO nanoparticles were precipitated with ethanol and then separated by SuperMag Separator™ (Ocean Nanotech, Springdale, AR), washed three times with ethanol. The resulted IO nanoparticles were redispersed in water, which turned into a brownish solution. Casein was pretreated with 0.01 M NaOH solution to form soluble base. The treated casein powder was added into the IO nanoparticle solution with a molar ratio of IO nanoparticle: casein at 1:200. The mixture was shaken gently at room temperature for about 4 h. Freshly prepared glutaraldehyde solution (0.4%, with the molar ratio of glutaraldehyde:casein at 1:2) was then added dropwise into the above mixture solution under magnetic stirring. This crosslink reaction was allowed to proceed for 1 h. The resulting CNIO product was washed with water several times through Ultra-4 centrifuge tubes with a cut off size of 100 kDa, then collected by magnetic separation and redispersed in water. The stock solution of CNIOs was stored at 4 °C for further use. The pH-dependent tests were conducted by adjusting the CNIO dispersion with diluted HCl or NaOH. The pH adjusted CNIO dispersions were then gently shaken at room temperature for 1 h to allow the sufficient reformation. The hydrodynamic size, surface charge, and MRI relaxation properties of the particles were studied to investigate the pH dependent stability of CNIOs.

Characterization of CNIOs

The morphology and size of CNIOs were studied using transmission electron microscope (TEM, Hitachi H-7500 accelerating voltage 75 kV). Typically, TEM samples were prepared by dropping diluted nanoparticle solutions on a carbon coated copper grid and air dried. For the negative staining, 1% phosphotungstic acid (PTA) aqueous solution was used to stain the background to visualize the protein coating, after a drop of CNIO solution was deposited on the copper grid and the solvent was wicked away. The hydrodynamic size (in diameter) and surface charge of nanoparticles in the aqueous solution were evaluated using a dynamic light scattering (DLS) instrument (Malvern Zeta Sizer Nano S-90) equipped with a 22 mW He-Ne laser operating at 632.8 nm. The averaged sizes were obtained from three measurements (10 runs per measurement) for each sample using number-weighted statistics. The Fourier

transform infrared spectroscopy (FTIR) spectra were collected on a PerkinElmer Spectrum 100 FT-IR spectrometer (Bucks, UK). UV-vis absorption spectra were obtained with a scanning spectrophotometer (Shimadzu UV-2401PC) with a slit width of 1.0 nm.

Measurements of transverse relaxation time and relaxivity

The transverse T_2 relaxation properties of CNIOs at different pH conditions were determined using a 3T MRI scanner (Magnetom Tim Trio, Siemens Medical Solutions, Erlangen, Germany). Solutions of CNIOs and amphiphilic polymer coated iron oxide nanoparticles (SHP15),⁶ which have the same iron oxide core as CNIO, were prepared with Fe concentrations varying from 0.006 to 0.089 mM. The phantom tubes containing those solution samples were placed in the MRI scanner. A T_2 -weighted fast spin echo imaging sequence with a repetition time (TR) of 3200 ms and echo time (TE) of 60 ms was used to evaluate the contrast effect of different nanoparticle solutions. To measure the transverse relaxation time T_2 , a multi-echo spin echo sequence was used with a TR of 2000 ms and 20 different TEs, starting at 10 ms with increments of 10 ms. Signal intensity (SI) of each region of interest (ROI) was measured for each concentration at different TEs. The values of T_2 relaxation times at different concentrations were derived from the fitting of the average SI data using a non-linear exponential equation.

Cytotoxicity evaluation

Cytotoxicity of CNIOs was assessed in vitro by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Mouse macrophage RAW264.7 cells were detached and seeded in 96-well flat-bottom microplates at 5,000 cells per well. After 24 h recovery at 37 °C, the medium was replaced with 200 μ L medium containing CNIOs at various concentrations (5, 10, 20, 50, 100, and 200 μ g Fe/mL). For the control sample, fresh medium without CNIOs was added. After 24 h of incubation at 37 °C, 20 μ L of MTT solution (5 mg/mL) was added into each well following a 3 h of incubation. After removing the culture media, the precipitated formazan was then dissolved in DMSO. Finally, a microplate reader (Biotech Synergy2) was used to measure the absorbance of all samples (n=5 per group) at 540 nm. Cell viability was determined by comparing the absorbance of cells incubated with CNIOs to that of the control cells incubated without CNIOs.

MRI of CNIOs in mice

All animal experiments were conducted following a protocol approved by Institutional Animal Care and Use Committee (IACUC). CNIOs were injected into Balb/c mice (n=3) through the tail vein at a dosage of 2.5 mg Fe/kg of mouse body weight. Animals were anesthetized by i.p. injection of a ketamine-xylazine mixture (95:5 mg/kg) before being placed in a 3T MRI scanner. T_2 -weighted fast spin echo images were acquired using a volumetric wrist coil in the coronal sections covering the whole mouse body before and 20, 40, 60, 150 min, 24 and 48 h after injection of nanoparticle contrast agents. The imaging parameters included: TR of 3600 ms, TE of 32 ms, matrix of 320 \times 128, field of view (FOV) of 120 \times 60 mm², flip angle of 150°, and slice thickness of 1.00 mm. The signal-to-noise ratio (SNR) was calculated according to the equation: $SNR = SI_{\text{mean}}/SD_{\text{noise}}$. The relative contrast enhancement at each time point was defined as signal decrease $\Delta SNR = (SNR_{\text{pre}} - SNR_{\text{post}})/SNR_{\text{pre}}$.

Conjugation of CNIOs with an EGFR Targeting Ligand

The human EGFR specific single chain fragment of anti-EGFR antibody (ScFvEGFR) expressing plasmid (ScFv B10) was kindly provided by Dr. Gregory Adams at Fox Chase Cancer Center, Philadelphia, PA. The ScFvEGFR of anti-EGFR antibody was produced using an established procedure published previously⁴¹ and then conjugated to CNIOs via a

covalent link of the carboxyl group of ScFvEGFR and the amine group of casein coating.^{42,43} Briefly, ScFvEGFR (1 mg) was reacted with NHS (0.25 mg) and EDAC (0.5 mg) in MES buffer solution (1 M, pH 5.5) for 15 min. Then CNIOs dispersed in borate buffer solution (0.5 M, pH 8.5) was added. The mixture was allowed to react for 2 h. The product was collected by SuperMag SeparatorTM, and washed with deionized water.

Specific cell binding of ScFvEGFR-CNIOs

Breast cancer MDA-MB-231 (over expressing EGFR) and MCF7 (expressing EGFR at a very low level) cells were seeded in 8-well chamber slides at the concentration of 50,000 cells per well. After recovering for 24 h, the media was replaced with that contained ScFvEGFR-CNIOs at the concentrations of 0, 0.10 and 0.25 mg Fe/mL. Cells were incubated at 37 °C for 4 h. The cell monolayer was then rinsed with PBS, and fixed with 4% paraformaldehyde in PBS solution. Prussian blue staining for iron was performed to investigate the specific binding of ScFvEGFR-CNIOs to cells with EGFR expression. Briefly, freshly prepared 10% potassium ferrocyanide (II) trihydrate and 20% HCl solution were mixed together and added to wells containing fixed cells. After incubating for 1 h, the working solution was removed, and the cells were washed with PBS. Counterstaining was performed by adding the nuclear fast red solution and incubating for 5 min. Then the cells were dehydrated with 70% and 100% ethanol, and rinsed in xylene. The slides were mounted and examined by a light microscope.

RESULTS AND DISCUSSION

Synthesis and characterization of CNIOs

The hydrophobic IOs with a core size of 15.1 ± 0.6 nm (diameter), as shown in the TEM image in Figure 1a, were coated with oleic acid and only soluble in nonpolar solvent (e.g., chloroform, hexane). After oleic acid was exchanged with oligosaccharides, IO nanoparticles were subsequently coated with casein to obtain water-soluble CNIOs (inset in Figure 1a). TEM measurement showed that the core size of CNIOs remained unchanged (~ 15 nm) after the ligand exchange process (Figure 1b). However, the number-weighted hydrodynamic diameter of nanoparticles changed from 17.6 to 18.5 nm after exchanging with oligosaccharides, and further increased to 30.5 nm after the formation of casein coating (Figure 1c). The changes in hydrodynamic size suggested the expected transition of different types of surface coating at different stages in the preparation. Negative staining allowed for visualizing a layer of 4-nm thick protein coating around the IO nanoparticles (inset in Figure 1b). Successful coating of casein molecules onto the nanoparticle surface was further confirmed by the surface charge changes. The surface zeta potential changed from -18.8 ± 4.9 mV to -38.0 ± 3.9 mV after attachment of casein proteins. The substantial increase in negative surface charge is likely attributed to the presence of a large number of carboxyl groups in casein. Size exclusion gel electrophoresis was used to determine the amount and purity of the obtained CNIOs. CNIOs exhibited a slower moving band (Figure 1d), compared to that of the IO nanoparticles without casein coating, indicating the increased size of CNIOs after the protein encapsulation. Gel code blue staining, which stains for the presence of casein, further confirmed the casein coating on the CNIO sample with a strong blue band in the location corresponding to CNIOs. No such blue band was observed for the IO nanoparticles without casein coating because of the absence of protein.

Fourier transform infrared (FTIR) spectra were acquired for further demonstration of the presence of casein coating on CNIOs (Figure 2). A characteristic peak from the Fe-O stretching band of iron oxide was observed at 586 cm^{-1} . The formation of casein coating on the nanoparticles was confirmed by the characteristic peaks from amide bands of protein in the IR spectra of CNIOs, compared with pure casein. Peaks at 1646 cm^{-1} and 1521 cm^{-1}

referred to C=O and C-N stretching from amide I and II, and the band at 1300–1200 cm^{-1} referred to C-N stretching and N-H deformation. In comparison with CNIOs, the IR spectra of oleic acid and oligosaccharides coated IO nanoparticles only displayed peaks from C=C stretching (1616 cm^{-1} for IO, 1637 cm^{-1} for SIO) and C-H bending (1409 cm^{-1} for IO, 1384 cm^{-1} for SIO). Using the Bradford assay which measures the protein content, we estimated that approximately 50 casein molecules were assembled on each IO nanoparticle.

Prepared CNIOs were easily dispersed in the aqueous solution. Aqueous CNIOs suspension was stable for months in storage at 4 °C without noticeable precipitation. Furthermore, the hydrodynamic size of CNIOs remained unchanged after 48 h incubation in the physiological condition of either phosphate buffer (PBS, pH 7.4) or serum-contained cell culture medium at room temperature (Figure 3).

MRI relaxation properties of CNIOs

To evaluate the MRI contrast enhancing capability of CNIOs, the transverse relaxivity and MRI signal changes of aqueous CNIO solutions with different Fe concentrations were investigated on a 3T MRI scanner. For comparison, amphiphilic polymer coated iron oxide nanoparticles (SHP15, with carboxyl groups on the surface, $-30\sim-50$ mV) with the same core size (15 nm) were selected.⁶ As shown in Figure 4a, substantially stronger hypointense contrast in T_2 -weighted spin echo images were observed in CNIO samples compared to those of SHP15 at the same iron concentrations. The decrease of MRI signal in T_2 -weighted images was iron concentration dependent. Transverse relaxation time T_2 at each iron concentration were determined by fitting the MRI signal intensities at different echo times ($n=20$) with an exponential function. Transverse relaxivity r_2 were calculated from slopes of the linear correlation between the relaxation rates (i.e., $1/T_2$) and iron concentrations (Figure 4b). The calculated r_2 was 273 $\text{mM}^{-1}\text{s}^{-1}$ for CNIOs, compared to 109 $\text{mM}^{-1}\text{s}^{-1}$ for SHP15. Thus, with casein coating, CNIOs exhibited an r_2 almost 2.5-fold higher than that of SHP15 coated with amphiphilic polymer. The increase of r_2 for CNIOs was further confirmed by the magnetic susceptibility measurement (Figure S4). The complex susceptibility for CNIOs is 0.043 at the frequency 1000 Hz, which is 1.4 times higher than that of SHP15 (~ 0.030). The increased relaxivity leads to higher sensitivity for detecting abnormalities, allowing for the same imaging quality at a reduced dosage with less toxicity concern.

Importantly, the increase in r_2 of CNIOs suggests that the coating material and surface properties play important roles in modulating MRI contrast enhancing effect. The unique structure and properties of casein changed the interface between the nanoparticle and bulk water medium. As it is known, the dipolar interactions between the particle magnetic moments and the surrounding water protons resulted in shortening T_2 relaxation time and proton dephasing. The higher and more efficient MRI contrast from CNIOs is possibly caused by the high water permeability of the coating, allowing water molecules to access and diffuse in and out of the inner/outer layers. Meanwhile, the high affinity of casein coating to water molecules may promote the interactions and diffusion of surrounding water molecules around the particles.^{44,45} Moreover, casein molecules have abundant hydrate function groups that can increase the exchange between the hydrated water molecules and ones in bulky surrounding. Another possible interpretation for the substantially increased r_2 is that some casein molecules may be covalently conjugated to the particle surface through the phosphate groups,⁴⁶ reducing the exclusion of water molecules from the particle surface and facilitating the exchange between bulk water and those residing on the casein surface. Similar phenomena were observed from human serum albumin and other protein coated IO nanoparticles.^{47,48} In addition to the hydrophilicity and water diffusion effect of the coating materials, less surface defects or deformation in the reductive environment during the modification may also contribute to the higher MRI contrast enhancement.

pH-responsive properties of CNIOs

Similar to pure CN (pI~4.2–5.8),²⁰ CNIOs were found to be highly pH-responsive and exhibit U-shaped dispersibility as a function of pH. Zeta potential measurements showed that the surface charge of CNIOs shifted from negative to positive as the pH value decreased from 8.0 to 2.0 (Figure 5a). This shift was caused by the neutralization of negative surface charge due to the pH decrease. The isoelectric point (pI) for CNIOs was determined to be ~pH 4.0, when the surface charge was neutralized to zero. The electrostatic repulsion between the particles decreased, thus leading to the aggregation of CNIOs. As shown in DLS data, particle sizes increased from 30.5 nm (pH 7.0) to 132 nm (pH 4.0) by forming loose aggregates. When the pH was decreased further, from 4.0 to 2.0, the surface charge became positive (~25.4 mV), providing sufficient electrostatic repulsion between particles, and thus promoted the dissociation of aggregates and the recovery of single dispersion with a size ~30 nm. Similarly, after the pH was adjusted back to 7.0 by acid titration, aggregates of CNIOs formed at pH 4.0 were dissociated to single dispersed constituent particles (Figure S1). Though the aggregates formed faster and larger after the first cycle of pH modulation, this aggregation-dissociation process was reversible up to 5 cycles. TEM images indicated that no obvious aggregates of CNIOs existed at pH 7.0 after 5 cycles (Figure S2). UV-vis absorption spectra of CNIO suspensions at different pH conditions revealed higher absorption at pH 4.0 than that at pH 7.0 (Figure S3), which also confirmed the aggregation of CNIOs at pH 4.0. Both single dispersed CNIOs and aggregated-CNIOs showed the characteristic absorption peak at 280 nm, which is attributed to the tryptophan, tyrosine, and cysteine residues in casein.

Since the influence of aggregation on the relaxation rate of single dispersed magnetic nanoparticles provides the potential to optimize the parameter for improved sensitivity and quantification, it has attracted much attention recently.^{32,49–55} Early studies showed the relationship between transverse relaxivity, r_2 , and the size of aggregates, D , could be divided into three regimes: 1) motional averaging regime (MAR), where r_2 is proportional to D^2 ; 2) static dephasing regime (SDR), where r_2 reaches to a maximum plateau, and is independent of D ; and 3) echo limited regime (ELR), where r_2 is proportional to $1/D^2$.^{50,56} The initial increase of r_2 can be attributed to the interactions between the small magnetic cores inside the aggregates, which enhance the magnetic moment of the nanocrystals, thus increasing the induced magnetic field inhomogeneity.^{45,57} However, a further increase in the cluster size of aggregates causes exclusion of the water molecules from the inner surface of the particle within polymer coating, altering the relaxation regime.^{48,50,56} In most reported cases, significantly increased r_2 relaxivity in aggregates or clusters of IO nanoparticles were based on nanoparticles either coated with polymers or encapsulated in micelles or liposomes, where the hydrophobic inner layer of the coating polymers or liposomes may strongly exclude the water molecules from the particle surface.^{45,50–54,58} For the CNIOs reported in this study, the MRI contrast enhancing effect was fairly constant and stable over the pH range of 4.0–8.0 (Figure 5b). This unique MRI property of CNIOs is likely to be contributed by the high affinity for water as well as the highly porous and water permeable structure of the protein coating, which allows for the nearby water molecules to maintain their molecular motion in the similar microenvironment even after they form the loose aggregates at pI 4.0. The loose structure of the CNIO aggregates differs from those compact multicore polymer coated or liposome or micelle encapsulated nanoparticle clusters previously reported in the literatures. Moreover, the distance between the nanoparticles in the CNIO aggregates is likely long, so that the interaction between each magnetic particle core is weak. Thus we did not observe a change of overall r_2 relaxivity of CNIO aggregates comparing to that of CNIO single cores. In fact, the observed constant transverse relaxivity and MRI contrast enhancing effect over the pH range of 4.0–8.0 provided indirect evidence that the high hydrophilicity and low diffusion restraints for water molecules moving in the protein layer contribute to the

much higher r_2 values of CNIOs. This unique phenomenon in CNIOs may lead to a new approach for developing high transverse relaxivity MRI contrast agents through promoting surface hydrophilicity, not just increasing the nanocrystal size. Nonetheless, further investigation is needed for a better understanding of such properties that contribute to relaxivities and MRI contrast enhancement as new classes of magnetic nanoparticles and surface coating materials are developed for MRI applications.

Cytotoxicity of CNIOs

In order to investigate the biocompatibility, cytotoxicity of CNIOs was evaluated using MTT assay by incubating macrophage RAW264.7 cells with medium containing CNIOs at different concentrations (5–200 $\mu\text{g Fe/mL}$) for 24 h. The cell viability was tested by MTT assay and normalized to the control samples. The cells incubated with CNIOs survived even at the highest iron concentration at 200 $\mu\text{g Fe/mL}$, showing viability ~90% compared to the control (Figure 6). These results suggested that these newly developed CNIOs are biocompatible and suitable for biomedical applications.

MRI contrast enhancement of CNIOs in mice

To further test the MRI contrast enhancing capability in vivo, CNIOs were intravenously (i.v.) administered into Balb/c mice at the dosage of 2.5 mg Fe/kg of mouse body weight. T_2 -weighted MRI was performed before and after injection. As shown in Figure 7a, hypointensities induced by CNIOs can be readily observed in liver and spleen at 20 min after injection. The signal-to-noise ratio (SNR) increased ~76% and ~52% in liver and spleen, respectively. The contrast in liver began to decrease after 24 h of injection (Figure 7b), possible due to the liver clearance. The contrast enhancement indicated the accumulation of CNIOs in these organs, demonstrating that CNIOs could be potentially used as effective T_2 -weighted MRI contrast agents. Biodistribution studies revealed the increase of iron concentration in liver and spleen after i.v. injection (Figure S5). Additionally, Prussian blue staining identified the presence of CNIOs in these organs. However, lower uptake of CNIOs by liver and spleen was observed in comparison with the polymer coated particles (SHP15) with the same size and surface charge (Figure S6).

Specific targeting to cancer cells with EGFR targeted CNIOs

Specific targeting of ScFvEGFR-CNIOs (with hydrodynamic size ~35.0 nm, Figure S6) to cancer cells was determined by co-incubating cells with ScFvEGFR-CNIOs, followed by Prussian blue staining for iron. Human breast cancer MDA-MB-231 and MCF7 cells were selected as target and non-target control cell lines. As shown in Figure 8, the cellular uptake of ScFvEGFR-CNIOs by MDA-MB-231 cells (over-expressing EGFR) was significant and in a dose-dependent manner. In comparison, little cellular uptake was observed in MCF7 cells (low level of expressing EGFR) treated with ScFvEGFR-CNIOs.

CONCLUSIONS

We have produced a new class of protein coated iron oxide nanoparticles using milk protein casein. Through ligand exchange and subsequent encapsulation of magnetic IO nanoparticles with casein, the prepared CNIOs showed excellent water solubility and stability in the pH range of 5.0–8.0 with a pI of 4.0. Compared with the IO nanoparticles with same hydrophobic IO core but coated with conventional synthetic polymer, these CNIOs exhibited substantially higher relaxivity and improved MRI contrast. Therefore, CNIOs potentially may provide high MRI sensitivity at a reduced dosage. The prepared CNIOs also show pH-responsive properties. Loose and soluble aggregates of CNIOs were formed near the pI~4.0. However, this was reversible as the aggregates dissociated to monodispersed single core form when the solution pH was adjusted back to 7.0. It is noticed

that no significant change was found for the transverse relaxation properties and MRI contrast enhancing effect at a pH range of 4.0 and 7.0. Furthermore, the carboxylic functional groups on the protein coating allow for the conjugation of bioactive moieties, such as biomarker specific targeting ligands. These results have demonstrated that CNIOs may provide a promising new class of MRI contrast agents, and could be extended to other protein coated nanoconstructs in biomedical applications.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Prof. Xiqun Jiang of Nanjing University for stimulating discussions on the potential use of milk proteins for biomedical applications, and Dr. Gregory Adams of Fox Chase Cancer for providing ScFvEGFR expressing plasmid, and Ms. Heather Price Boldt and Ms. Jessica Paulishen for their assistances in editing and proofreading the manuscript. This work is supported in part by the Emory Molecular Translational Imaging Center of National Institutes of Health (NIH) and National Cancer Institute (NCI)'s in vivo Cellular and Molecular Imaging Center grant (ICMIC, P50CA128301-01A10003 to HM and LY), NCI's Cancer Nanotechnology Partnership Project (CNPP) grant (U01CA151810-02 to LY and HM), and NIH/NCI's R01CA154846-02 (to HM and LY).

ABBREVIATIONS

CN	casein
IO	iron oxide
MRI	magnetic resonance imaging
PAA	poly(acrylic acid)
PEI	polyethylenimine
GSH	glutathione
DMSO	dimethyl sulfoxide
CNIOs	casein-coated iron oxide nanoparticles
DMF	N-dimethylformamide
MTT	3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide
EDC	1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride
Sulfo-NHS	N-hydroxysulfosuccinimide
TEM	transmission electron microscope, PTA, phosphotungstic acid
DLS	dynamic light scattering
FTIR	Fourier transform infrared spectroscopy
SI	Signal intensity
SNR	signal-to-noise ratio
ScFvEGFR	human EGFR specific single chain fragment of anti-EGFR antibody
SIO	oligosaccharide coated iron oxide nanoparticle

References

1. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani K, Laurent S. *Chem Rev.* 2011; 111:253. [PubMed: 21077606]

2. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. *Nat Rev Cancer*. 2012; 12:39. [PubMed: 22193407]
3. Laurent S, Bridot JL, Elst LV, Muller RN. *Future Med Chem*. 2010; 2:427. [PubMed: 21426176]
4. Reddy LH, Arias JL, Nicolas J, Couvreur P. *Chem Rev*. 2012; 112:5818. [PubMed: 23043508]
5. Huang J, Zhong X, Wang L, Yang L, Mao H. *Theranostics*. 2012; 2:86. [PubMed: 22272222]
6. Chen K, Xie J, Xu H, Behera D, Michalski MH, Biswal S, Wang A, Chen X. *Biomaterials*. 2009; 30:6912. [PubMed: 19773081]
7. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. *Angew Chem Int Ed*. 2008; 47:7284.
8. Tassa C, Shaw SY, Weissleder R. *Acc Chem Res*. 2011; 44:842. [PubMed: 21661727]
9. Xu Y, Qin Y, Palchoudhury S, Bao Y. *Langmuir*. 2011; 27:8990. [PubMed: 21644795]
10. Zhang T, Ge J, Hu Y, Yin Y. *Nano Lett*. 2007; 7:3203. [PubMed: 17854231]
11. Duan H, Kuang M, Wang X, Wang YA, Mao H, Nie S. *J Phys Chem C*. 2008; 112:8127.
12. Zhang B, Li Q, Yin P, Rui Y, Qiu Y, Wang Y, Shi D. *ACS Appl Mater Interfaces*. 2012; 4:6479. [PubMed: 23151093]
13. Meldrum FC, Wade VJ, Nimmo DL, Heywood BR, Mann S. *Nature*. 1991; 349:684.
14. Valero E, Tambalo S, Marzola P, Ortega-Munoz M, Lopez-Jaramillo FJ, Santoyo-Gonzalez F, de Dios Lopez J, Delgado JJ, Calvino JJ, Cuesta R, Dominguez-Vera JM, Galvez N. *J Am Chem Soc*. 2011; 133:4889. [PubMed: 21384882]
15. Meldrum FC, Heywood BR, Mann S. *Science*. 1992; 257:522. [PubMed: 1636086]
16. Fan K, Cao C, Pan Y, Lu D, Yang D, Feng J, Song L, Liang M, Yan X. *Nat Nanotechnol*. 2012; 7:459. [PubMed: 22706697]
17. Lee, J-h; Jung, MJ.; Hwang, YH.; Lee, YJ.; Lee, S.; Lee, DY.; Shin, H. *Biomaterials*. 2012; 33:4861. [PubMed: 22475532]
18. Sangeetha J, Philip J. *Colloids Surf, A*. 2012; 406:52.
19. Farrell HM, Jimenez-Flores R, Bleck GT, Brown EM, Butler JE, Creamer LK, Hicks CL, Hollar CM, Ng-Kwai-Hang KF, Swaisgood HE. *J Dairy Sci*. 2004; 87:1641. [PubMed: 15453478]
20. Modler HW. *J Dairy Sci*. 1985; 68:2195.
21. Livney YD. *Curr Opin Colloid Interface Sci*. 2010; 15:73.
22. Holt C, Horne DS. *Neth Milk Dairy J*. 1996; 50:85.
23. Horne DS. *Curr Opin Colloid Interface Sci*. 2006; 11:148.
24. Holt C, de Kruif CG, Tuinier R, Timmins PA. *Colloids Surf, A*. 2003; 213:275.
25. Farrell HM Jr, Malin EL, Brown EM, Qi PX. *Curr Opin Colloid Interface Sci*. 2006; 11:135.
26. Dalgleish DG. *Soft Matter*. 2011; 7:2265.
27. Flett KL, Corredig M, Goff HD. *J Food Sci*. 2010; 75:433.
28. Holt C. *Adv Protein Chem*. 1992; 43:63. [PubMed: 1442324]
29. Dalgleish DG. *J Dairy Sci*. 1998; 81:3013.
30. Song F, Zhang LM, Yang C, Yan L. *Int J Pharm*. 2009; 373:41. [PubMed: 19429286]
31. Sahu A, Kasoju N, Bora U. *Biomacromolecules*. 2008; 9:2905. [PubMed: 18785706]
32. Liu C, Yao W, Zhang L, Qian H, Wu W, Jiang X. *Chem Comm*. 2010; 46:7566. [PubMed: 20848035]
33. Zimet P, Rosenberg D, Livney YD. *Food Hydrocolloids*. 2011; 25:1270.
34. Bachar M, Mandelbaum A, Portnaya I, Perlstein H, Even-Chen S, Barenholz Y, Danino D. *J Controlled Release*. 2012; 160:164.
35. Elzoghby AO, Samy WM, Elgindy NA. *J Controlled Release*. 2012; 161:38.
36. Abd El-Salam MH, El-Shibiny S. *Int J Dairy Technol*. 2012; 65:13.
37. Huang J, Xie J, Chen K, Bu L, Lee S, Cheng Z, Li X, Chen X. *Chem Comm*. 2010; 46:6684. [PubMed: 20730157]
38. Sugisawa H, Edo H. *J Food Sci*. 1966; 31:561.
39. Sun XM, Li YD. *Angew Chem Int Ed*. 2004; 43:597.
40. Yu WW, Falkner JC, Yavuz CT, Colvin VL. *Chem Comm*. 2004:2306. [PubMed: 15489993]

41. Zhou Y, Daryl C, Zou H, Hayes ME, Adams GP, Kirpotin DB, JDM. *J Mol Biol.* 2007; 371:934. [PubMed: 17602702]
42. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S. *Small.* 2009; 5:235. [PubMed: 19089838]
43. Peng X, Wang Y, Huang D, Wang Y, Shin HJ, Chen Z, Spewak MB, Mao H, Wang X, Wang Y, Chen Z, Nie S, Shin DM. *Acs Nano.* 2011; 5:9480. [PubMed: 22032622]
44. Paquet C, de Haan HW, Leek DM, Lin HY, Xiang B, Tian G, Kell A, Simard B. *Acs Nano.* 2011; 5:3104. [PubMed: 21428441]
45. Poeselt E, Kloust H, Tromsdorf U, Janschel M, Hahn C, Masslo C, Weller H. *Acs Nano.* 2012; 6:1619. [PubMed: 22276942]
46. Lartigue L, Innocenti C, Kalaivani T, Awwad A, Duque MdMS, Guari Y, Larionova J, Guerin C, Montero J-LG, Barragan-Montero V, Arosio P, Lascialfari A, Gatteschi D, Sangregorio C. *J Am Chem Soc.* 2011; 133:10459. [PubMed: 21604803]
47. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. *Biomaterials.* 2008; 29:4012. [PubMed: 18649936]
48. Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2009; 1:299. [PubMed: 20049798]
49. Roch A, Gossuin Y, Muller RN, Gillis P. *J Magn Magn Mater.* 2005; 293:532.
50. Balasubramaniam S, Pothayee N, Lin Y, House M, Woodward RC, St Pierre TG, Davis RM, Riffle JS. *Chem Mater.* 2011; 23:3348.
51. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R. *Nat Biotechnol.* 2002; 20:816. [PubMed: 12134166]
52. Larsen BA, Haag MA, Serkova NJ, Shroyer KR, Stoldt CR. *Nanotechnology.* 2008:19.
53. Osborne EA, Jarrett BR, Tu C, Louie AY. *J Am Chem Soc.* 2010; 132:5934. [PubMed: 20373802]
54. Kaittanis C, Santra S, Santiesteban OJ, Henderson TJ, Perez JM. *J Am Chem Soc.* 2011; 133:3668. [PubMed: 21341659]
55. Chen H, Yeh J, Wang L, Khurshid H, Peng N, Wang AY, Mao H. *Nano Res.* 2010; 3:852.
56. Tromsdorf UI, Bigall NC, Kaul MG, Bruns OT, Nikolic MS, Mollwitz B, Sperling RA, Reimer R, Hohenberg H, Parak WJ, Forster S, Beisiegel U, Adam G, Weller H. *Nano Lett.* 2007; 7:2422. [PubMed: 17658761]
57. Qiu P, Jensen C, Charity N, Towner R, Mao C. *J Am Chem Soc.* 2010; 132:17724. [PubMed: 21117657]
58. Cha J, Kwon YS, Yoon TJ, Lee JK. *Chem Comm.* 2013; 49:457. [PubMed: 23100091]




Figure 1.

TEM images of a) hydrophobic IO nanoparticles before modification and b) after coated with casein (CNIOs). Inset of a) is a photograph of hydrophobic IO nanoparticles dispersed in chloroform (left) and water-soluble CNIOs (right); inset of b) is a negative stained TEM image that shows a protein coating (bright layer surrounding the particles); c) dynamic light scattering (DLS) data showing the changes of hydrodynamic size (in diameter) of IO nanoparticles before modification, after ligand exchange, and after being coated with casein; d) pictures of gel electrophoresis analysis of casein (CN), oligosaccharide coated iron oxide nanoparticles (SIO), casein-coated iron oxide nanoparticles (CNIO) with a gel running marker (frontier, DNA loading dye) (top panel), and corresponding gel code blue staining (bottom panel).




Figure 2. FT-IR spectra of hydrophobic iron oxide (IO) nanoparticles, oligosaccharide coated iron oxide (SIO) nanoparticles, casein-coated iron oxide (CNIO) nanoparticles and casein (CN).




Figure 3. Stability of CNIOs in water, PBS and RPMI1640 culture medium as assessed by DLS. The particle size did not show significant change after 48-h incubation in those mediums at room temperature.




Figure 4. a) T₂-weighted spin echo MR images of CNIOs and SHP15 at different concentrations; b) transverse relaxation rates ($1/T_2$, s⁻¹) of CNIOs and SHP15 as a function of the iron concentration (mM).




Figure 5. a) Plots of changes in hydrodynamic size (red solid cycle) and surface charge (blue triangle) of CNIOs as a function of pH; b) transverse relaxivity r_2 of CNIOs as a function of pH.




Figure 6. Cell viability of RAW264.7 macrophage cells treated with various concentrations of CNIOs for 24 h measured by MTT assay.




Figure 7.

a) T₂-weighted MR images of a mouse before and after injection of CNIOs at a dosage of 2.5 mg Fe/kg per mouse body weight; b) relative MR signal-to-noise ratio (SNR) in liver, spleen and muscle.




Figure 8.

a) Representative microscope images for Prussian blue staining of MDA-MB-231 (over-expressing EGFR) and MCF7 (low level of expressing EGFR) cells after incubated with ScFvEGFR-CNIOs at 37 °C for 4 h, stained IO nanoparticles present as blue dots; b) Percentages of Prussian blue positive cells analyzed by ImageJ revealed pronounced cellular uptake of ScFvEGFR-CNIOs by MDA-MB-231 cells.


**Scheme 1.**

Illustration of the exchange-encapsulation process for coating iron oxide (IO) nanoparticles with casein to obtain casein coated iron oxide nanoparticles (CNIO).